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PRACTICE POINTER
Novel psychoactive substances: identifying and
managing acute and chronic harmful use
Derek K Tracy 1  2, David M Wood 3  4, David Baumeister 5
1Oxleas NHS Foundation Trust, London; 2Cognition, Schizophrenia and Imaging Laboratory, Department of Psychosis Studies, the Institute of
Psychiatry, Psychology and Neuroscience, King’s College London; 3Clinical Toxicology, Guy’s and St Thomas’ NHS Foundation Trust and King’s
Health Partners, London, UK; 4School of Life Sciences and Medicine, King’s College London, London, UK; 5Department of Psychology, the Institute
of Psychiatry, Psychology and Neuroscience, King’s College London
Identifying and managing acute drug related harms and
problematic substance misuse cuts across medical specialties.
Data suggest that clinicians are seeking readily accessible
information on novel psychoactive substances (NPS), incorrectly
known as “legal highs.” Clinicians may encounter acutely
disturbed or unwell patients, individuals with harm or
dependency related to chronic NPS use, and those reporting
incidental consumption that might require psychoeducation and
monitoring. Such assessments will have more successful and
meaningful outcomes if clinicians are aware of the spectrum of
NPS available and how they might affect their patient.
The linked clinical update1 describes the different classes of
NPS and their effects. This article provides practical advice to
the non-specialist on how to approach an assessment of
individuals using NPS, including examples of acute and chronic
use.
Exploring NPS use
A sensitive, non-judgmental approach is essential. Key aspects
of the history are applicable in all scenarios. Boxes 1 and 2
cover specific issues relevant to emergency and longer term
presentations. Patients may be concerned about being criticised
for using drugs, and they might be uncertain of, but worried
about, the potential harms and available services for those using
NPS. Individuals can also be fearful of legal consequences of
disclosure, and the principle and limits of confidentiality should
be discussed. Adopt an empathic line of questioning, such as
“I can imagine it might be difficult or worrying to talk about
drug/NPS use. My role is to try understand any problems you
are having, and to see how I can help.”
Include a history, mental state, and physical examination
(particularly blood pressure, heart rate, temperature, and level
of consciousness) in the initial assessment. Explore the type of
drug or NPS used and the method and frequency of
consumption, and ask about acute and chronic harms associated
with use (box 3). Unlike established recreational drugs such as
cannabis, heroin, or cocaine, most standard urinary drug tests
have limited sensitivity and specificity to NPS. Nevertheless,
a urinary drug test can prove useful in helping to establish if
other drugs are being used.
Consider whether there are relevant social and environmental
issues that might precipitate or perpetuate substance misuse.
The National Drug Treatment Monitoring System identified
specific factors associated with longer term, harmful use in those
under 18 years old16: early onset (<15 years old) and poly-drug
use, antisocial behaviour, being affected by others’ drug use or
domestic violence, and being a child in need of or on a
protection plan.
Evaluating motivation to change
There are no well evidenced screening tools for identifying
problematic NPS use. Not everyone who uses NPS, or any other
established recreational drug, necessarily needs or wants
professional help. However, if a patient discloses use of NPS,
view this as an opportunity to provide information and discuss
potential risks in a non-judgmental manner. Also consider
whether to signpost the patient to relevant specialist healthcare
services such as substance misuse, sexual health, and mental
health teams.
Motivational interviewing is a goal-oriented technique to engage
individuals and reduce their ambivalence to change behaviour.
Rather than tackle drug use “head on” with (at least perceived)
messages of just stopping, which can be challenging and may
provoke disengagement, motivational interviewing encourages
individuals to focus on their own goals and how they might plan
for them. For example, “It sounds as if things have been difficult
for a while. Have you thought about aspects of life that might
be holding you back from where you would like to be, or what
you would like to achieve?” The FRAMES approach17 is a well
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What you need to know
• Most standard urinary drug tests have limited sensitivity and specificity to novel psychoactive substances (NPS)
• Discuss risks and encourage reduction in the frequency and quantity of harmful NPS use, but be cautious with benzodiazepines or
opioids where sudden discontinuation can lead to physical withdrawal
• Offer referral to drug and alcohol treatment services or other professionals, such as psychiatry, sexual health, or social services when
appropriate
Box 1: Case scenario 1: emergency presentation
A 29 year old man is bought into the emergency department by ambulance after acting erratically with staff at a nightclub. On arrival, he is
pacing, agitated, and mildly aggressive. On examination, his heart rate is 130 bpm, blood pressure 160/95 mm Hg, temperature 38.5°C,
and he has dilated pupils, increased tone and hyperreflexia in his lower limbs, and 5-6 beats of inducible ankle clonus. His friends told
paramedics he had taken a ‘white powder’ which he bought as a legal high on the internet.
Spotting acute use
A more direct line of questioning is required in acute presentations. The clinical presentation in this example is consistent with use of a
serotonergic drug (either an established recreational drug or NPS variant) and serotonin syndrome (toxicity)2—characterised as a triad of
mental status changes, autonomic hyperactivity, and neuromuscular abnormalities, although clinical features are not always consistent.
In terms of NPS, mephedrone is commonly implicated given its high reported prevalence of use and availability.3-5 From a treating clinician’s
perspective, although knowing the precise drug(s) used helps provide better informed patient advice before discharge, management of acute
stimulant toxicity is broadly similar regardless of whether an individual has taken an NPS or an established recreational drug. Accidental or
intentional overdose of selective serotonin reuptake inhibitors (SSRIs) cause a similar picture, so it is important to ask about prescribed
medications and other medical and psychiatric problems. Finally, certain medical conditions may present with similar clinical features (such
as severe sepsis or encephalitis).
Assessment and management of mephedrone toxicity
Although broadly similar to that for established recreational stimulants, the full clinical picture associated with acute toxicity of mephedrone
remains incompletely understood.6 7 However, signs and symptoms associated with use have been described in user self reports, surveys,
and cases confirmed by toxicology. The most commonly reported clinical features are agitation or aggression, tachycardia, and hypertension
(>25% of users). Others include (in 10-25% of cases) palpitations, insomnia, hallucinations, paranoia, nausea, vomiting, chest pain,
paraesthesia, confusion, and anxiety; and in <10% of cases, seizures, headache, hyperpyrexia, cold or blue extremities, tremor, and reduced
level of consciousness.3-13 Some case series report concomitant use of other drugs, and thus some of the symptoms reported may relate to
these rather than mephedrone.11
Some reports indicate that the acute toxicity of mephedrone and other NPS stimulants is more prolonged than that seen with established
recreational stimulants. For example, the UK National Poisons Information Service reported 45% of patients had symptoms for more than
24 hours after use of mephedrone, and 30% had symptoms for more than 48 hours.14
Management includes preventing further exposure to serotonergic drugs (including prescribed medications) and treating the stimulant clinical
features. Benzodiazepines may be used to help reduce sympathomimetic toxicity (agitation, hypertension, tachycardia), in the same way
that they are used for patients with toxicity after harmful use of MDMA, cocaine, and amphetamines. The oral 5-HT2A antagonist cyproheptadine
helps directly reduce the effects of the excess serotonin concentrations seen in such instances.
Hyperpyrexia (core temperature of >39°C) is a medical emergency, and the patient’s temperature needs to be reduced rapidly. Initial
measures include cold intravenous fluids, removing excess clothing, use of benzodiazepines and cyproheptadine; the most effective method
for reducing temperature seems to be packing the patient in ice, with very rapid temperature decreases reported. If clinicians are unsure
how to manage a patient, or the patient has severe toxicity (such as hyperpyrexia), they are advised to seek advice from their local toxicology
service.
Box 2: Case scenario 2: chronic use
A 24 year old woman presents to her GP with low mood and feeling “up and down.” She admits she is concerned about her use of “spice,”
which she has been smoking regularly for several years, but she is not sure she wants professional help with this at the moment. She says
that most of her friends use similar drugs, and she does not think she would discontinue use completely.
Exploring harmful use and dependency
This case presents a pattern of chronic novel psychoactive substance (NPS) use. Diagnostically, “harmful use” typically involves an intermittent
binge pattern of use that can be damaging to an individual’s physical or mental health. Dependency is a more complex syndrome of
behavioural, cognitive, and physiological symptoms that can accompany repeated use. Three of the following six criteria are required for a
diagnosis of dependency on any drug: (a) desiring the substance; (b) difficulty controlling the amount consumed; (c) tolerance to its effects;
(d) withdrawal effects; (e) giving primacy to use of the substance and neglecting alternatives; and (f) persisting use despite these difficulties.15
Avoid the use of pejorative terms or labels such as “addict” and ensure a supportive motivational approach to discussions. In instances of
both harmful use and dependency, agreeable individuals can be referred to substance misuse services, though the management of
dependency can be more complex. In the case of benzodiazepine and opioid dependency, this will usually involve stabilisation on suitable
replacement therapy, followed by detoxification (“detox”) on a staggered reduction regimen. Care may be provided in community or inpatient
settings, depending upon individuals’ requirements and locally available services, and is sometimes followed by a period of psychosocial
rehabilitation (“rehab”). Various specialist psychosocial interventions are available for patients with dependency or harmful use who wish to
modify their behaviour.
Box 3: Areas to explore and document in a history of novel psychoactive substance (NPS) use
Drug class(es)—Stimulant, cannabinoid, hallucinogen (dissociatives and psychedelics), depressant (opioids and benzodiazepines)
Method(s) of use—Oral ingestion, nasal insufflation (“snorting”), intravenous injection, rectal insertion
Drug consumption patterns—Quantity, frequency; concomitant consumption of prescribed or over-the-counter medication or alcohol or
other recreational drugs. Use of cigarettes
Acute and chronic harmful effects—Physical and psychological sequelae, risks from impulsive behaviour, including sexual health. Impact
on mental health and social functioning. Identification of individual vulnerabilities, risk of exploitation by others, and potential safeguarding
issues towards others
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established model used in many substance misuse services and
can be a useful strategy in this regard (box 4).
Harm minimisation
Harm reduction begins with encouraging decreasing the
frequency and quantity of NPS use, but care must be taken in
the case of novel benzodiazepines or opioids because sudden
discontinuation can lead to physical withdrawal. Where relevant,
discuss risks associated with injecting drugs, signpost to a needle
exchange or injecting service, and offer referral for HIV and
hepatitis testing. Anecdotally, there have been reports of an
increase in intravenous NPS use in “chem sex” parties and that
some new drug users have poor injection technique, with
associated increased risk of thrombosis and abscesses and other
infections.
When to refer
Consider harm in a wider social context. Assessment and support
from social services may be required for individuals, or their
families, who may be vulnerable or at risk of harm from or
towards others.
Offer interventions within the limits of expertise and clinical
setting, and recommend referral to drug and alcohol treatment
services or other healthcare professionals, such as psychiatry,
when appropriate.
A “strengths based approach” should help highlight positive
environmental factors and aspects of personal resilience that
will help individuals through recovery. For example, inquire
into, and highlight back to the patient, relevant social factors
such as good family and relationship support, and individuals’
desire and motivation to change their life.
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Box 4: The FRAMES motivational interviewing model for encouraging engagement and self responsibility with
drug use
Feedback—Discuss the potential adverse outcomes of drug use, individualised to the person’s pattern of use, and listen to their responses
Responsibility—Emphasise that it is up to the individual to decide if they wish to change their behaviour
Advice—Straightforward advice on how drug use can be changed
Menu—Provide the individual with their therapeutic options, and facilitate their decision making
Empathy—Have a non-judgmental and warm clinical approach
Self efficacy—Project optimism that they have the ability to positively change their life if they so wish
Resources for healthcare professionals
• UK National Poisons Information Service (www.npis.org) and its clinical toxicology database TOXBASE (www.toxbase.org)—If you
need advice or information that is not available on TOXBASE then call NPIS for clinical support
• NEPTUNE (novel psychoactive treatment: UK network) (http://neptune-clinical-guidance.co.uk)—Comprehensive clinical guidance
on party drugs
• Wood DM, Dargan PI. Understanding how data triangulation identifies acute toxicity of novel psychoactive drugs. J Med Toxicol
2012;8:300-3
• Baumeister D, Tojo LM, Tracy DK. Legal highs: staying on top of the flood of novel psychoactive substances. Ther Adv Psychopharmacol
2015;5:97-132—Review of the neurobiology of NPS
• GOV.UK. New Psychoactive Substances (NPS) resource pack (www.gov.uk/government/publications/new-psychoactive-substances-
nps-resource-pack)—UK Home Office NPS resource pack for “informal educators and frontline practitioners”
• EMCDDA. EU drug markets report (www.emcdda.europa.eu/start/2016/drug-markets)—Guide to the European illicit drugs’ market
Resources for drug consumers and the public
• FRANK (friendly confidential drugs advice). Legal highs (www.talktofrank.com/legalhighs)—UK based general information guide for
patients and the lay public
• EROWID (www.erowid.org)—Non-profit, international, drug-consumer-led website providing non-judgmental advice and guidance
• Rise Above (http://riseabove.org.uk/tag/drinking-smoking-drugs/)—Website by NHS England for children and adolescents about
substance misuse, mental health, and other social issues
• Bowden-Jones O. The Drug Conversation: How to talk to your child about drugs. Royal College of Psychiatrists, 2016
• Global Drug Survey (www.globaldrugsurvey.com)—Information for, and international survey of, NPS consumers
• Sumnall H, Atkinson A. The new Psychoactive Substances Bill–a quick introduction. (www.cph.org.uk/blog/the-new-psychoactive-
substances-bill-a-quick-introduction/)—Guide to legislative changes in the UK
How patients were involved in the creation of this article
An individual receiving residential care for mental health issues related to chronic “spice” use was interviewed in the preparation of this
paper. The proposal and plan of the papers was discussed with him, and he wished to remain anonymous in the production of this work.
His input particularly helped highlight the need to emphasise individuals’ strengths and supports in any assessment of substance misuse.
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